State Farm Mutual Q4 2025: The $127B Value Engine Driven by Eli Lilly and Caterpillar
State Farm's highly concentrated Q4 portfolio reveals massive conviction in Eli Lilly (10.5%) and Caterpillar (7.8%), showcasing a unique defensive value strategy.
Institutional Conviction at Scale
State Farm Mutual Automobile Insurance Co's Q4 2025 13F filing stands out for its remarkable concentration and unwavering commitment to a select group of blue-chip leaders. Managing a $127.32 billion portfolio with only 114 unique positions, State Farm operates with a level of conviction rarely seen among institutional giants, where portfolios typically span thousands of names.
State Farm Mutual Top 5 Holdings Q4 2025 ($M)
The Eli Lilly and Caterpillar Dominance
The headline of the filing is the firm's massive overweight positioning in Eli Lilly (LLY) and Caterpillar (CAT). Combined, these two positions represent over 18% of the total US equity book. With a $13.4 billion stake in LLY and a $10.0 billion stake in CAT, State Farm is signaling profound confidence in the pharmaceutical giant's GLP-1 growth trajectory and the industrial leader's global infrastructure dominance.
AUM Concentration: Top 10 vs Others (%)
A Defensive Value Anchor
While tech-heavy portfolios have dominated recent headlines, State Farm maintains a robust anchor in traditional value sectors. Top positions in Johnson & Johnson (JNJ), Illinois Tool Works (ITW), and Walmart (WMT) reinforce a defensive posture. Even its technology exposure is focused on established leaders like Apple (AAPL) and Microsoft (MSFT), which together account for roughly 9% of the portfolio.
High Concentration, Low Churn
The Q4 data reveals a firm that rarely changes its core thesis. With only 3 new entries and 4 total exits, State Farm is the epitome of the "buy-and-hold" institutional investor. The top 10 positions account for 48.9% of the total portfolio, a concentration level that would be considered high even for many active hedge funds. This suggests that for State Farm, the best trading move is often no move at all.
Summary for Value Investors
State Farm's portfolio serves as a masterclass in long-term capital allocation. By maintaining massive, multi-billion dollar stakes in secular winners like Eli Lilly while anchoring the book with defensive industrials and healthcare, the firm continues to build a resilient, multi-decade value engine. For a complete view of all 114 holdings, explore the State Farm Mutual 13F profile.
Related Research
Explore all researchWolverine Trading's latest 13F reveals a highly concentrated $138.7 billion portfolio led by a massive $15.8 billion stake in the SPY ETF and significant bets on NVDA and TSLA.
Apr 5, 2026
Corient Private Wealth's portfolio expanded by over 133% in Q4 2025, driven by a hyper-aggressive pivot into Tesla (+3325% shares) and Netflix (+3776% shares).
Apr 5, 2026
The 220-year-old London-based asset manager's US equity book reveals a distinctly European conviction — GOOGL as the #3 holding at 6.03%, plus aggressive adds in TEVA (+261%), CX (+406%), and new global commodity ETF positions.
Mar 30, 2026
Simplex Trading reported a $177.41B Q4 2025 13F, but the filing reads less like a stock portfolio and more like an options-heavy market-structure book. That distinction is the whole story.
Apr 1, 2026
CalPERS' latest 13F reveals $174.90B in reported AUM with VOO at 11.89% — nearly $20B in one S&P 500 ETF. Combined with NVDA at 8.55%, the top-2 holdings account for 20.44% of this pension giant's portfolio.
Mar 30, 2026